Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

View all »   RSSRecent Releases

Dec 12, 2016
Arbutus Provides Additional Data from the ARB-1467 Phase II Clinical Trial in HBV Patients

Nov 14, 2016
Arbutus Presents HBV Drug Combination Studies at AASLD


View all »Events & Presentations

Dec 12, 2016 at 1:30 PM PT
Arbutus Biopharma Corporation Conference Call

Nov 11, 2016
2016 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)